Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for JBM (Healthcare)'s Median PS Value or its related term are showing as below:
HKSE:02161's Price-to-Median-PS-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.86 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
JBM (Healthcare) (HKSE:02161) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
JBM (Healthcare)'s Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.92
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JBM (Healthcare) Median PS Value Related Terms
JBM (Healthcare) Median PS Value Historical Data
* Premium members only.
The historical data trend for JBM (Healthcare)'s Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JBM (Healthcare)'s Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JBM (Healthcare) Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JBM (Healthcare)'s Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where JBM (Healthcare)'s Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. JBM (Healthcare)'s Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was HK$1.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JBM (Healthcare) (HKSE:02161) has a Median PS Value of HK$0.00 as of Aug. 04, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on JBM (Healthcare) and its competitors. According to the industry distribution chart, JBM (Healthcare) ranks #999999 out of 547 companies in the Drug Manufacturers industry.
Is JBM (Healthcare)'s Median PS Value too high?
JBM (Healthcare)'s current Median PS Value is HK$0.00. Based on the distribution chart, JBM (Healthcare) ranks #999999 out of 547 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, JBM (Healthcare) has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does JBM (Healthcare)'s Median PS Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, JBM (Healthcare) ranks #999999 out of 547 companies for Median PS Value. This places JBM (Healthcare) in the lower half of its industry. The industry median Median PS Value is 0.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.86, based on 547 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on JBM (Healthcare) and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JBM (Healthcare)'s current Median PS Value is HK$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JBM (Healthcare) stock overvalued right now?
Based on GuruFocus' analysis, JBM (Healthcare) (HKSE:02161) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.08, compared to a current price of HK$1.92 — trading 7.7% below its estimated fair value. The current Median PS Value is HK$0.00. JBM (Healthcare)'s overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For JBM (Healthcare) (HKSE:02161), the current Median PS Value is HK$0.00 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JBM (Healthcare) (HKSE:02161) Overvalued in 2026?
Based on GuruFocus' analysis, JBM (Healthcare) stock appears to be undervalued.
The current stock price of HK$1.92 is trading 7.7% below its estimated GF Value™ of HK$2.08.
GuruFocus considers JBM (Healthcare) to be Fairly Valued.
Key valuation signals for HKSE:02161:
Median PS Value: HK$0.00
GF Value™: HK$2.08 vs. price of HK$1.92 (7.7% below fair value)
No single metric tells the full story. See the HKSE:02161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.
86GF Score
Get the complete analysis for HKSE:02161
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02161 has been successfully added to your 
